Frazier Life Sciences entities reported beneficial ownership stakes in Achieve Life Sciences common stock. Frazier Life Sciences Public Fund, L.P. (FLSPF) and related entities collectively report shared beneficial ownership of 6,625,788 shares (6.5%). Frazier Life Sciences XI entities hold 61,958 shares (0.1%) and Frazier Life Sciences XII entities hold 777,090 shares (0.8%). The filing cites 53,239,988 shares outstanding as of March 24, 2026 and notes 49,418,069 shares sold in a private placement on April 17, 2026. The statement discloses additional pre-funded warrants and common warrants with exercise subject to a 9.99% beneficial ownership limitation and clarifies voting/dispositive powers are held as reported.
Positive
None.
Negative
None.
Insights
Concentrated stake: FLSPF reports a meaningful single-holder position of 6,625,788 shares (6.5%).
The filing lists exact beneficial holdings by Frazier Life Sciences funds: 6,625,788 shares for FLSPF, 61,958 for FLS XI, and 777,090 for FLS XII. The percentages are computed using March 24, 2026 outstanding shares and the April private placement.
Key dependencies include the exercise limits on the disclosed warrants and the governance of the general partner entities. Subsequent disclosures may show changes in ownership if warrants are exercised subject to the 9.99% cap.
Voting and dispositive power is shared through fund structures and committee-managed GPs.
The filing explains that certain general partners are managed by investment committees (three- or four-member committees) and that no individual committee member is attributed direct beneficial ownership of the fund-held shares. Voting and disposition powers are reported as shared where applicable.
Investors should note the filing’s explicit attribution language and the disclosed ownership percentages when assessing potential influence; governance effects depend on future concentration changes or warrant exercises.
Key Figures
FLSPF shares:6,625,788 sharesFLSPF percent:6.5%FLS XI shares:61,958 shares+4 more
7 metrics
FLSPF shares6,625,788 sharesBeneficially owned by Frazier Life Sciences Public Fund, L.P.
FLSPF percent6.5%Percent of common stock as reported in cover page calculations
FLS XI shares61,958 sharesHeld by Frazier Life Sciences XI entities
FLS XII shares777,090 sharesHeld by Frazier Life Sciences XII entities
Shares outstanding (anchor)53,239,988 sharesShares outstanding as of March 24, 2026 (Form 10-K)
Private placement49,418,069 sharesShares sold in private placement on April 17, 2026 (Form 8-K)
Common Warrants (FLSPF)6,714,992 warrantsCommon Warrants held by FLSPF, exercise subject to 9.99% limit
Key Terms
Pre-Funded Warrants, Common Warrants, beneficial ownership limitation
3 terms
Pre-Funded Warrantsfinancial
"holds Pre-Funded Warrants to purchase 89,204 shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrantsfinancial
"Common Warrants to purchase 6,714,992 shares of Common Stock"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
beneficial ownership limitationregulatory
"cannot be exercised if aggregate beneficial ownership would exceed 9.99% of the number of shares"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Achieve Life Sciences, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
004468500
(CUSIP Number)
04/17/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,625,788.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,625,788.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,625,788.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,625,788.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,625,788.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,625,788.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,625,788.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,625,788.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,625,788.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
61,958.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
61,958.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
61,958.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
61,958.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
61,958.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
61,958.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
61,958.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
61,958.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
61,958.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
Frazier Life Sciences XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
777,090.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
777,090.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
777,090.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
FHMLS XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
777,090.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
777,090.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
777,090.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
CUSIP Number(s):
004468500
1
Names of Reporting Persons
FHMLS XII, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
777,090.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
777,090.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
777,090.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 53,239,988 shares of Common Stock outstanding on March 24, 2026, as set forth in the Issuer's Annual Report on Form 10-K filed with the SEC on March 24, 2026, and (ii) 49,418,069 shares of Common Stock sold by the Issuer in a private placement transaction on April 17, 2026, as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on April 16, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Achieve Life Sciences, Inc.
(b)
Address of issuer's principal executive offices:
22722 29th Drive SE, Suite 100, Bothell, WA, 98021.
Item 2.
(a)
Name of person filing:
The entities filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
(b)
Address or principal business office or, if none, residence:
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite 200B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
004468500
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 6,625,788 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.
FLS XI directly holds 61,958 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.
FLS XII directly holds 777,090 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII.
The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Pre-Funded Warrants") or warrants to acquire shares of Common Stock (the "Common Warrants" and together with the Pre-Funded Warrants, the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Pre-Funded Warrants to purchase 89,204 shares of Common Stock and Common Warrants to purchase 6,714,992 shares of Common Stock, (ii) FLS XI holds Pre-Funded Warrants to purchase 834 shares of Common Stock and Common Warrants to purchase 62,792 shares of Common Stock and (iii) FLS XII holds Pre-Funded Warrants to purchase 10,462 shares of Common Stock and Common Warrants to purchase 787,552 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
04/24/2026
FHMLSP, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
04/24/2026
FHMLSP, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:
04/24/2026
Frazier Life Sciences XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
04/24/2026
FHMLS XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
04/24/2026
FHMLS XI, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:
04/24/2026
Frazier Life Sciences XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:
04/24/2026
FHMLS XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
